StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$16.70+0.80 (+5.03%)

Close on Nov 17, 2026Market cap $1.65BP/E –Yield –

Ultragenyx Pharmaceutical profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Ultragenyx Pharmaceutical's profit margin for the twelve months ending Jun 30, 2026 was -81.7%. For fiscal 2025 it was -85.4%, against -101.6% the year before. The highest annual figure on record is -68.8% in fiscal 2020.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-85.4%+16.2
FY2024Dec 31, 2024-101.6%+38.3
FY2023Dec 31, 2023-139.9%+54.8
FY2022Dec 31, 2022-194.7%−65.5
FY2021Dec 31, 2021-129.2%−60.4
FY2020Dec 31, 2020-68.8%+319.5
FY2019Dec 31, 2019-388.3%−4.6
FY2018Dec 31, 2018-383.7%+11183.6
FY2017Dec 31, 2017-11567.3%+173300.3
FY2016Dec 31, 2016-184867.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-43.0%+25.9
Q1 FY2026Mar 31, 2026-136.0%−27.4
Q4 FY2025Dec 31, 2025-62.0%+18.9
Q3 FY2025Sep 30, 2025-112.8%−17.1
Q2 FY2025Jun 30, 2025-68.9%+20.6
Q1 FY2025Mar 31, 2025-108.6%+48.2
Q4 FY2024Dec 31, 2024-80.9%+16.3
Q3 FY2024Sep 30, 2024-95.7%+67.1
Q2 FY2024Jun 30, 2024-89.5%+58.1
Q1 FY2024Mar 31, 2024-156.8%+6.3
Q4 FY2023Dec 31, 2023-97.2%+49.7
Q3 FY2023Sep 30, 2023-162.8%+107.4
Q2 FY2023Jun 30, 2023-147.6%+29.5
Q1 FY2023Mar 31, 2023-163.2%+27.4
Q4 FY2022Dec 31, 2022-146.9%−0.1
Q3 FY2022Sep 30, 2022-270.2%−180.8
Q2 FY2022Jun 30, 2022-177.0%−36.3
Q1 FY2022Mar 31, 2022-190.6%−53.6
Q4 FY2021Dec 31, 2021-146.9%−120.6
Q3 FY2021Sep 30, 2021-89.4%−4.9
Q2 FY2021Jun 30, 2021-140.8%−181.8
Q1 FY2021Mar 31, 2021-137.0%+190.8
Q4 FY2020Dec 31, 2020-26.2%+237.3
Q3 FY2020Sep 30, 2020-84.5%+353.5
Q2 FY2020Jun 30, 202041.0%+451.7
Q1 FY2020Mar 31, 2020-327.8%+204.6
Q4 FY2019Dec 31, 2019-263.5%+276.6
Q3 FY2019Sep 30, 2019-438.0%+304.3
Q2 FY2019Jun 30, 2019-410.7%+1.5
Q1 FY2019Mar 31, 2019-532.4%−815.8
Q4 FY2018Dec 31, 2018-540.1%+2845.6
Q3 FY2018Sep 30, 2018-742.2%+39271.4
Q2 FY2018Jun 30, 2018-412.1%+1425327.9
Q1 FY2018Mar 31, 2018283.3%+58758.1
Q4 FY2017Dec 31, 2017-3385.7%–
Q3 FY2017Sep 30, 2017-40013.6%–
Q4 FY2016Dec 31, 2016-1425740.0%–
Q3 FY2016Sep 30, 2016-58474.8%–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?